Clinical meaning
Cyanide is one of the most rapidly lethal poisons known, capable of causing death within minutes at sufficient doses. It exists in multiple forms: hydrogen cyanide (HCN, a volatile gas), cyanide salts (potassium cyanide/KCN, sodium cyanide/NaCN), cyanogenic glycosides (amygdalin in bitter almonds, cassava, apple seeds), and cyanide-releasing compounds (sodium nitroprusside, acetonitrile in artificial nail remover). The most common cause of cyanide poisoning in developed countries is smoke inhalation from structural fires -- combustion of synthetic materials (polyurethane, nylon, wool, silk, plastics) releases hydrogen cyanide gas, and fire victims often have combined cyanide and carbon monoxide (CO) poisoning, which is synergistically lethal. Industrial exposure in mining, electroplating, chemical manufacturing, and photography is another important source. The mechanism of cyanide toxicity centers on the inhibition of cytochrome c oxidase (Complex IV), the terminal enzyme of the mitochondrial electron transport chain (ETC). Under normal aerobic metabolism, cells generate ATP through oxidative phosphorylation: electrons from NADH and FADH2 are passed through Complexes I, II, III, and IV of the ETC embedded in the inner mitochondrial membrane, with molecular oxygen (O2) serving as the final electron acceptor at Complex IV (cytochrome c oxidase). The energy released by electron transfer is used to pump protons (H+) across the inner mitochondrial membrane, creating an electrochemical gradient that drives ATP synthesis by ATP synthase (Complex V). This process generates 36-38 ATP molecules per glucose molecule and is responsible for >90% of cellular ATP production. Cyanide binds with high affinity to the iron (Fe3+) center of cytochrome a3 (the oxygen-binding subunit of cytochrome c oxidase), preventing the transfer of electrons to molecular oxygen. This effectively shuts down the entire ETC because electrons cannot flow to their terminal acceptor. When Complex IV is inhibited, the upstream complexes (I, II, III) cannot transfer their electrons either (they become fully reduced and cannot accept new electrons), halting the entire oxidative phosphorylation process. The proton gradient across the inner mitochondrial membrane collapses, and ATP synthesis ceases. The cell is forced to rely entirely on anaerobic glycolysis for ATP production, generating only 2 ATP per glucose (compared to 36-38 from aerobic metabolism) and producing excessive lactic acid. This creates a profound lactic acidosis that is a hallmark laboratory finding of cyanide poisoning. Because the cells cannot utilize oxygen despite its presence, oxygen accumulates in the venous blood -- the venous blood remains oxygenated (bright red rather than the normal dark blue/purple), producing the classic finding of 'cherry red' venous blood and an abnormally NARROW arteriovenous oxygen difference. The pulse oximetry reading is paradoxically normal or high despite the patient being in cellular hypoxia -- the oxygen is present in the blood but cannot be used by the mitochondria (this is called histotoxic/cytotoxic hypoxia). The organs most vulnerable to cyanide toxicity are those with the highest oxygen consumption and mitochondrial density: the brain (most sensitive -- neuronal death within minutes), the heart (cardiac arrest from myocardial ATP depletion), and the liver. The clinical presentation reflects this vulnerability: within seconds to minutes of significant cyanide exposure, patients develop headache, confusion, agitation, seizures (from brain ATP depletion), followed rapidly by loss of consciousness, respiratory arrest, cardiovascular collapse, and death. The classic description includes the 'bitter almond' odor on the patient's breath (though 20-40% of people cannot detect this due to a genetic variation in olfactory receptor genes), cherry-red skin (from saturated venous blood and cyanomethemoglobin formation -- though this is often a late or postmortem finding), and the paradox of a normoxic pulse oximetry reading in a critically ill patient with severe metabolic acidosis. The treatment of cyanide poisoning is a medical emergency requiring immediate antidote administration. Two antidote strategies exist: (1) The hydroxocobalamin (Cyanokit) approach -- hydroxocobalamin (vitamin B12a precursor) directly binds cyanide with extremely high affinity, forming cyanocobalamin (vitamin B12), which is nontoxic and renally excreted. This is the preferred first-line antidote because it is safe, effective, does not cause methemoglobinemia, does not cause hypotension, and can be given empirically to smoke inhalation victims who may have concurrent CO poisoning. (2) The traditional cyanide antidote kit (Taylor kit/Lilly kit) uses a sequential two-step approach: first, an agent to generate methemoglobin (amyl nitrite inhaled or sodium nitrite IV), because methemoglobin (Fe3+) has higher affinity for cyanide than cytochrome c oxidase, pulling cyanide away from the mitochondria and forming cyanmethemoglobin; second, sodium thiosulfate IV, which provides sulfur substrate for the enzyme rhodanese (sulfurtransferase), which converts cyanide to thiocyanate (a relatively nontoxic compound excreted by the kidneys). The nitrite-based approach has significant limitations: inducing methemoglobinemia reduces the oxygen-carrying capacity of hemoglobin, which is dangerous in patients with concurrent CO poisoning (already compromised oxygen delivery) and in anemic patients; nitrites also cause hypotension through nitric oxide-mediated vasodilation. For these reasons, hydroxocobalamin has largely replaced the nitrite-thiosulfate approach as first-line therapy, particularly in the pre-hospital and fire rescue setting. Nursing priorities include recognizing cyanide poisoning in the differential diagnosis of smoke inhalation victims with severe metabolic acidosis (lactic acid >8 mmol/L), maintaining airway patency and providing 100% high-flow oxygen (even though the cells cannot use it, maintaining high PaO2 maximizes the competitive displacement of cyanide from cytochrome oxidase), immediately administering the appropriate antidote, and monitoring for cardiovascular collapse requiring advanced cardiac life support.